Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Oropharyngeal candidiasis may be the first manifestation of human immunodeficiency viral (HIV) infection, and more than 90% of patients with the acquired immunodeficiency syndrome (AIDS) develop the disease. Although numerous antifungal agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole), have largely replaced older topical antifungals (gentian violet, nystatin) in the management of the disease in these patients. A concern in these patients is clinical relapse, which appears to be dependent on degree of immunosuppression and is more common with clotrimazole and ketoconazole than with fluconazole or itraconazole. Candida esophagitis is also of concern, since it occurs in more than 10% of patients with AIDS. Fluconazole is an integral part of management. A cyclodextrin oral solution formulation of itraconazole has similar clinical response rates as fluconazole and is an effective alternative. In patients with fluconazole-resistant mucocutaneous candidiasis, treatment options include itraconazole and amphotericin B oral suspension and parenteral preparation.

Original languageEnglish (US)
Pages (from-to)76-87
Number of pages12
JournalPharmacotherapy
Volume19
Issue number1 I
DOIs
StatePublished - Jan 20 1999
Externally publishedYes

Fingerprint

Fluconazole
Candidiasis
Virus Diseases
Itraconazole
Acquired Immunodeficiency Syndrome
Clotrimazole
Gentian Violet
Nystatin
Azoles
Ketoconazole
Esophagitis
Antifungal Agents
Cyclodextrins
Amphotericin B
Disease Management
Candida
Immunosuppression
Suspensions
Recurrence

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. / Vazquez, Jose Antonio.

In: Pharmacotherapy, Vol. 19, No. 1 I, 20.01.1999, p. 76-87.

Research output: Contribution to journalArticle

@article{7bfb60b16ff3494a97987683110517c5,
title = "Options for the management of mucosal candidiasis in patients with AIDS and HIV infection",
abstract = "Oropharyngeal candidiasis may be the first manifestation of human immunodeficiency viral (HIV) infection, and more than 90{\%} of patients with the acquired immunodeficiency syndrome (AIDS) develop the disease. Although numerous antifungal agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole), have largely replaced older topical antifungals (gentian violet, nystatin) in the management of the disease in these patients. A concern in these patients is clinical relapse, which appears to be dependent on degree of immunosuppression and is more common with clotrimazole and ketoconazole than with fluconazole or itraconazole. Candida esophagitis is also of concern, since it occurs in more than 10{\%} of patients with AIDS. Fluconazole is an integral part of management. A cyclodextrin oral solution formulation of itraconazole has similar clinical response rates as fluconazole and is an effective alternative. In patients with fluconazole-resistant mucocutaneous candidiasis, treatment options include itraconazole and amphotericin B oral suspension and parenteral preparation.",
author = "Vazquez, {Jose Antonio}",
year = "1999",
month = "1",
day = "20",
doi = "10.1592/phco.19.1.76.30509",
language = "English (US)",
volume = "19",
pages = "76--87",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1 I",

}

TY - JOUR

T1 - Options for the management of mucosal candidiasis in patients with AIDS and HIV infection

AU - Vazquez, Jose Antonio

PY - 1999/1/20

Y1 - 1999/1/20

N2 - Oropharyngeal candidiasis may be the first manifestation of human immunodeficiency viral (HIV) infection, and more than 90% of patients with the acquired immunodeficiency syndrome (AIDS) develop the disease. Although numerous antifungal agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole), have largely replaced older topical antifungals (gentian violet, nystatin) in the management of the disease in these patients. A concern in these patients is clinical relapse, which appears to be dependent on degree of immunosuppression and is more common with clotrimazole and ketoconazole than with fluconazole or itraconazole. Candida esophagitis is also of concern, since it occurs in more than 10% of patients with AIDS. Fluconazole is an integral part of management. A cyclodextrin oral solution formulation of itraconazole has similar clinical response rates as fluconazole and is an effective alternative. In patients with fluconazole-resistant mucocutaneous candidiasis, treatment options include itraconazole and amphotericin B oral suspension and parenteral preparation.

AB - Oropharyngeal candidiasis may be the first manifestation of human immunodeficiency viral (HIV) infection, and more than 90% of patients with the acquired immunodeficiency syndrome (AIDS) develop the disease. Although numerous antifungal agents are available, azoles, both topical (clotrimazole) and systemic (fluconazole, itraconazole), have largely replaced older topical antifungals (gentian violet, nystatin) in the management of the disease in these patients. A concern in these patients is clinical relapse, which appears to be dependent on degree of immunosuppression and is more common with clotrimazole and ketoconazole than with fluconazole or itraconazole. Candida esophagitis is also of concern, since it occurs in more than 10% of patients with AIDS. Fluconazole is an integral part of management. A cyclodextrin oral solution formulation of itraconazole has similar clinical response rates as fluconazole and is an effective alternative. In patients with fluconazole-resistant mucocutaneous candidiasis, treatment options include itraconazole and amphotericin B oral suspension and parenteral preparation.

UR - http://www.scopus.com/inward/record.url?scp=0032919163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032919163&partnerID=8YFLogxK

U2 - 10.1592/phco.19.1.76.30509

DO - 10.1592/phco.19.1.76.30509

M3 - Article

VL - 19

SP - 76

EP - 87

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1 I

ER -